Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02887183 · ClinicalTrials.gov registry record · Phase 4
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 794
- Enrollment target
NCT02887183 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 794 participants.
The verdict
NCT02887183, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 794 participants
- Enrollment target
Study Summary
This study was to determine early and more chronic changes in concentrations of biomarkers related to mechanisms of action (MOA) and effects of sacubitril/valsartan therapy over a period of 12 months, and correlated these biomarker changes with cardiac remodeling parameters, patient-reported outcomes and cardiovascular outcomes.
Interventions
- DRUG LCZ696 (sacubitril/valsartan)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 794 participants |
| Start Date | 2016-10-25 |
| Est. Completion | 2018-10-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02887183
The ClinicalTrials.gov registry entry for NCT02887183 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 794 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LCZ696 (sacubitril/valsartan) is the first listed.
NCT02887183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02887183 about?
NCT02887183 is a clinical study titled "Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.". This study was to determine early and more chronic changes in concentrations of biomarkers related to mechanisms of action (MOA) and effects of sacubitril/valsartan therapy over a period of 12 months, and correlated these biomarker changes with cardiac remodeling parameters, patient-reported outcome...
What is the current status of trial NCT02887183?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 794 participants. The study started on 2016-10-25. Estimated completion is 2018-10-22.
What interventions are being tested in trial NCT02887183?
The interventions under investigation include: LCZ696 (sacubitril/valsartan) (DRUG).
Who is sponsoring clinical trial NCT02887183?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.